Compare Stocks: RXST, AVNS, QDEL, and CERS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVNS Avanos Medical	$24.99	$24.97	$9.30 ▼ $25.49	$1.17B	1.57	700,357 shs	N/A
CERS Cerus	$2.58 -0.8%	$2.84	$1.17 ▼ $3.47	$519.93M	1.79	2.20 million shs	559,818 shs
QDEL QuidelOrtho	$13.82 -0.9%	$16.04	$9.92 ▼ $35.58	$947.71M	0.68	1.73 million shs	322,949 shs
RXST RxSight	$6.62 -5.8%	$5.95	$4.48 ▼ $13.22	$275.35M	1.16	964,178 shs	373,877 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVNS Avanos Medical	0.00%	0.00%	0.00%	-0.06%	+108.96%
CERS Cerus	-0.38%	-5.11%	+20.93%	-6.81%	+104.72%
QDEL QuidelOrtho	+1.45%	-6.44%	-21.23%	-8.82%	-50.62%
RXST RxSight	+0.57%	+10.19%	+11.76%	+37.84%	-19.20%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVNS Avanos Medical	$24.99	$24.97	$9.30 ▼ $25.49	$1.17B	1.57	700,357 shs	N/A
CERS Cerus	$2.58 -0.8%	$2.84	$1.17 ▼ $3.47	$519.93M	1.79	2.20 million shs	559,818 shs
QDEL QuidelOrtho	$13.82 -0.9%	$16.04	$9.92 ▼ $35.58	$947.71M	0.68	1.73 million shs	322,949 shs
RXST RxSight	$6.62 -5.8%	$5.95	$4.48 ▼ $13.22	$275.35M	1.16	964,178 shs	373,877 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVNS Avanos Medical	0.00%	0.00%	0.00%	-0.06%	+108.96%
CERS Cerus	-0.38%	-5.11%	+20.93%	-6.81%	+104.72%
QDEL QuidelOrtho	+1.45%	-6.44%	-21.23%	-8.82%	-50.62%
RXST RxSight	+0.57%	+10.19%	+11.76%	+37.84%	-19.20%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVNS Avanos Medical	1.50	Reduce	N/A	N/A
CERS Cerus	2.40	Hold	$5.25	106.94% Upside
QDEL QuidelOrtho	1.50	Reduce	$13.63	-0.04% Downside
RXST RxSight	1.92	Reduce	$8.37	23.13% Upside

Current Analyst Ratings Breakdown

Latest RXST, AVNS, QDEL, and CERS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2026	CERS Cerus	Freedom Broker Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$6.50
8/12/2026	QDEL QuidelOrtho	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/10/2026	RXST RxSight	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$8.00 ➝ $7.00
8/6/2026	RXST RxSight	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$5.50 ➝ $6.30
7/28/2026	RXST RxSight	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$9.00 ➝ $5.50
7/28/2026	RXST RxSight	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral ➝ Hold	$9.00 ➝ $5.50
7/20/2026	AVNS Avanos Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	QDEL QuidelOrtho	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/8/2026	QDEL QuidelOrtho	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$13.00 ➝ $18.00
7/7/2026	RXST RxSight	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$6.50
7/7/2026	RXST RxSight	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Underperform	$8.00 ➝ $6.50

(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVNS Avanos Medical	$715.90M	1.64	$3.42 per share	7.30	$16.73 per share	1.49
CERS Cerus	$221.55M	2.31	N/A	N/A	$0.35 per share	7.25
QDEL QuidelOrtho	$2.67B	0.35	$18.67 per share	0.73	$25.88 per share	0.53
RXST RxSight	$127.58M	2.22	N/A	N/A	$6.33 per share	1.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVNS Avanos Medical	-$72.90M	-$1.61	N/A	26.59	N/A	-10.39%	5.39%	3.97%	N/A
CERS Cerus	-$15.63M	-$0.03	N/A	N/A	N/A	-3.06%	-10.19%	-3.14%	11/5/2026 (Estimated)
QDEL QuidelOrtho	-$1.13B	-$15.41	N/A	9.27	N/A	-39.20%	4.88%	1.63%	11/4/2026 (Estimated)
RXST RxSight	-$38.94M	-$1.13	N/A	N/A	N/A	-36.80%	-17.35%	-14.70%	11/4/2026 (Estimated)

Latest RXST, AVNS, QDEL, and CERS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	QDEL QuidelOrtho	-$0.0488	$0.13	+$0.1788	-$1.36	$618.72 million	$630.90 million
8/5/2026	Q2 2026	RXST RxSight	-$0.3294	-$0.29	+$0.0394	-$0.29	$32.55 million	$33.74 million
7/30/2026	Q2 2026	CERS Cerus	-$0.0133	-$0.01	+$0.0033	-$0.01	$62.90 million	$63.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVNS Avanos Medical	N/A	N/A	N/A	N/A	N/A
CERS Cerus	N/A	N/A	N/A	N/A	N/A
QDEL QuidelOrtho	N/A	N/A	N/A	N/A	N/A
RXST RxSight	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVNS Avanos Medical	0.11	2.48	1.40
CERS Cerus	0.49	1.83	1.07
QDEL QuidelOrtho	1.43	1.39	0.76
RXST RxSight	N/A	4.07	3.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVNS Avanos Medical	95.17%
CERS Cerus	78.37%
QDEL QuidelOrtho	99.00%
RXST RxSight	78.78%

Insider Ownership

Company	Insider Ownership
AVNS Avanos Medical	2.33%
CERS Cerus	5.30%
QDEL QuidelOrtho	1.10%
RXST RxSight	10.05%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVNS Avanos Medical	2,287	46.85 million	45.76 million	Optionable
CERS Cerus	290	201.53 million	190.84 million	Optionable
QDEL QuidelOrtho	6,500	68.58 million	67.82 million	Optionable
RXST RxSight	220	41.59 million	37.41 million	Optionable

RXST, AVNS, QDEL, and CERS Headlines

Recent News About These Companies

Ilya Goldshleger Sells 2,041 Shares of RxSight (NASDAQ:RXST) Stock

September 3 at 7:07 AM | insidertrades.com

BlackRock Inc. Purchases Shares of 5,790,408 RxSight, Inc. $RXST

September 3 at 3:43 AM | marketbeat.com

RxSight (NASDAQ:RXST) COO Ilya Goldshleger Sells 2,041 Shares of Stock

September 2 at 11:07 PM | marketbeat.com

RxSight (NASDAQ:RXST) Insider Sells 2,041 Shares

September 2 at 11:07 PM | marketbeat.com

RxSight (NASDAQ:RXST) Insider Ronald Md Kurtz Sells 5,100 Shares

September 2 at 11:06 PM | marketbeat.com

RxSight (NASDAQ:RXST) CFO Sells 7,765 Shares

September 2 at 11:06 PM | marketbeat.com

Canada Pension Plan Investment Board Acquires Shares of 181,300 RxSight, Inc. $RXST

September 1 at 3:59 AM | marketbeat.com

Grandeur Peak Global Advisors LLC Has $3.48 Million Stock Holdings in RxSight, Inc. $RXST

August 31 at 4:31 AM | marketbeat.com

Algert Global LLC Grows Stake in RxSight, Inc. $RXST

August 30, 2026 | marketbeat.com

RxSight (NASDAQ:RXST) Lowered to Sell Rating by Wall Street Zen

August 29, 2026 | americanbankingnews.com

RxSight (NASDAQ:RXST) Stock Rating Lowered by Wall Street Zen

August 29, 2026 | marketbeat.com

Grandeur Peak Global Advisors LLC Takes Position in RxSight, Inc. $RXST

August 28, 2026 | marketbeat.com

540,208 Shares in RxSight, Inc. $RXST Acquired by Deutsche Bank AG

August 28, 2026 | marketbeat.com

RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference

August 26, 2026 | globenewswire.com

RxSight, Inc. $RXST Shares Acquired by Bank of America Corp DE

August 26, 2026 | marketbeat.com

Tocqueville Asset Management L.P. Makes New Investment in RxSight, Inc. $RXST

August 21, 2026 | marketbeat.com

Vitruvian Partners LLP Purchases New Holdings in RxSight, Inc. $RXST

August 19, 2026 | marketbeat.com

RxSight Inc.

August 18, 2026 | marketwatch.com

Walleye Capital LLC Takes Position in RxSight, Inc. $RXST

August 15, 2026 | marketbeat.com

RxSight, Inc. (NASDAQ:RXST) Receives Average Recommendation of "Reduce" from Brokerages

August 14, 2026 | marketbeat.com

RxSight (RXST) Q2 2026 Earnings Call Transcript

August 12, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXST, AVNS, QDEL, and CERS Company Descriptions

Avanos Medical NYSE:AVNS

$24.99 0.00 (0.00%)

As of 09/2/2026

Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

Cerus NASDAQ:CERS

$2.58 -0.02 (-0.77%)

As of 02:33 PM Eastern

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

QuidelOrtho NASDAQ:QDEL

$13.82 -0.13 (-0.93%)

As of 02:32 PM Eastern

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.

RxSight NASDAQ:RXST

$6.62 -0.41 (-5.83%)

As of 02:33 PM Eastern

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RXST, AVNS, QDEL, and CERS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RXST, AVNS, QDEL, and CERS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RXST, AVNS, QDEL, and CERS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXST, AVNS, QDEL, and CERS Company Descriptions

Avanos Medical NYSE:AVNS

Cerus NASDAQ:CERS

QuidelOrtho NASDAQ:QDEL

RxSight NASDAQ:RXST

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RXST, AVNS, QDEL, and CERS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RXST, AVNS, QDEL, and CERS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RXST, AVNS, QDEL, and CERS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXST, AVNS, QDEL, and CERS Company Descriptions

Avanos Medical NYSE:AVNS

Cerus NASDAQ:CERS

QuidelOrtho NASDAQ:QDEL

RxSight NASDAQ:RXST

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools